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Summary The characters in gingival fibroblasts derived from a nifedipine-reactive patient
(nifedipine responder: NIFr) and those from a nifedipine-nonreactive patient (nifedipine non-
responder: NIFn) are summarized, and investigated a possibility of tenidap, ()-5-chloro-2,3-
dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide, and 18a-glycyrrheti-
nic acid (18a-GA) as a therapeutics for gingival overgrowth caused by calcium channel blockers.
Tenidap discharges intracellular Ca2+ store, resulting in a depletion of intracellular Ca2+ store in
cultured human gingival fibroblasts. It also inhibited cell growth, DNA and collagen syntheses,
lowered intracellular pH in nicardipine responder cells, and enhanced matrix metalloproteinase-
1 formation in NIFr cells. 18a-GA inhibited cell proliferation and G1/S transition induced in NIFr
cells. It was also shown that cell cycle control proteins were down-stream targets in the growth-
inhibition activity of 18a-GA in NIFr cells. These results suggest that tenidap and 18a-GA might be
effective for the prevention of gingival overgrowth caused by calcium channel blockers.
# 2009 Japanese Association for Dental Science. Published by Elsevier Ireland. All rights reserved.
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Gingival overgrowth in response to anti-epileptics (phenytoin
and sodium valproate), immunosuppressants (cyclosporine
A), and calcium channel blockers (nifedipine, diltiazem,
verapamil, nicardipine, amlodipine, manidipine, and nisol-
dipine) is well-recognized. Particularly, many case reports
have implicated nifedipine (NIF), one of the dihydropyridine
calcium channel blockers, as a cause of gingival overgrowth
(first reported by Ramon et al. [1] and Lederman et al. [2]).
The incidence of gingival overgrowth due to NIF has been
reported to be 6.5% [3], 7.6% [4], more than 10% [5], 11.6%
[6], 15% [7], and 20% [8]. We also reported the incidences of
gingival overgrowth caused by amlodipine, diltiazem, man-
idipine, nicardipine, and nisoldipine were 1.1%, 4.1%, 1.8%,
0.5%, and 1.1%, respectively [4]. However, the mechanism of
the NIF-induced gingival overgrowth has not been well clar-
ified.We have previously demonstrated the difference on cell
growth, collagen synthesis, calcium response, intracellular
crosstalk, and cell cycle between gingival fibroblasts derived
from a NIF-reactive patient (NIF responder, NIFr) and those
from a NIF-nonreactive patient (NIF non-responder, NIFn).
In this review, the specific characters in NIFr and NIFn are
summarized, and a possibility of tenidap, ()-5-chloro-2,3-
dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-
carboxamide, and 18a-glycyrrhetinic acid (18a-GA) was
investigated as a therapeutics for gingival overgrowth caused
by calcium channel blockers.
2. Characterize NIFr and NIFn cells
2.1. Response to calcium channel blockers on
proliferation, DNA and collagen syntheses
In general, the histological examination of the gingival speci-
mens from patients reactive to NIF medication revealed large
bundles of dense collagenous fivers with a moderate increase
of fibroblasts in addition to epithelial hyperplasia with
acanthosis and parakeratosis, and elongation of the rete
pegs. Thus, it was thought interesting to focus on gingival
fibroblasts obtained from NIFr and NIFn. As the first step of
the investigation, the difference between NIFr cells and NIFn
cells was studied. NIFr cells exhibited greater proliferation
rates and DNA and collagen syntheses than NIFn cells in the
presence of 1 mM of calcium channel blockers (nifedipine,
diltiazem, nicardipine, and verapamil) or phenytoin [9].
Therefore, it is possible that gingival fibroblasts from NIF-
reactive patients may be also susceptible to the other cal-
cium channel blockers, which indicates that those patients
who developed gingival overgrowth because of NIF medica-
tion may also develop it in response to other calcium channelblockers. This was confirmed later, but not for nisoldipine
responder cells [10]. Thus, fibroblasts from patients reactive
to NIF and nicardipine medication gave a better cell prolif-
eration rate, DNA synthesis, and an increased number of EGF
receptors compared to non-drug-treated control, but not in
fibroblasts from patients reactive to nisoldipine medication.
In general, the presence of tooth and gingival crevice are
essential to generate drug-induced gingival overgrowth, sug-
gesting that the presence of gingival crevicular fluid might be
important for gingival overgrowth. Interleukin-1a (IL-1a)
predominates in gingival crevicular fluid and greater amount
of NIF is found in gingival crevicular fluid in the patients with
periodontal disease, it was interesting to investigate the
simultaneous effect of NIF and IL-1a on cell proliferation
and DNA synthesis. The presence of IL-1a resulted in greater
cell proliferation and DNA synthesis than in the presence of
NIF alone and NIFr cells showed greater response. The DNA
synthesis rate with a combination of NIF and IL-1a was also
higher than that for NIF or IL-1a alone. Thus, the interaction
between NIF and gingival inflammation might play an impor-
tant role in the pathogenesis of NIF-induced gingival over-
growth [11]. IL-1a also yielded significantly higher basic
fibroblast growth factor (bFGF) production and release,
and also enhanced bFGF mRNA expression. In addition, levels
of released bFGF were significantly higher in cells pretreated
with IL-1a, followed by bradykinin and thapsigargin in the
presence of extracellular Ca2+. The transient mobilization of
intracellular Ca2+ accelerated the release of bFGF in IL-1a-
pretreated cells, but not in untreated cells [12]. These
findings suggest that NIFr cells are more sensitive to NIF
and that IL-1a accelerate this sensitivity through bFGF for-
mation.
2.2. Response to stimulants on intracellular free
Ca2+ concentration
The cell proliferation in cultured fibroblasts involves a
sequence of biochemical events, which begin in part at
the cell surface by mitogen stimulation and progress tempo-
rally and spatially to the cell nucleus through signal trans-
duction pathways. Among the earliest of these events are
dramatic changes in intracellular free Ca2+ concentration in a
variety of cell types via a direct effect of inositol 1,4,5-
trisphosphate (IP3) on the ligand-activated calcium channels
in intracellular Ca2+-storing organelles [13,14]. Therefore, it
was interesting to investigate if there are any differences
between NIFr cells and NIFn cells against the stimulants, such
as bradykinin, thrombin, histamine, bombesin, prostaglan-
dins E2 and F2a, and platelet derived growth factor-BB. NIFn
cells showed a greater cytosolic calcium response to brady-
kinin, thrombin, prostaglandins E2 and F2a and platelet
derived growth factor-BB than NIFr cells. On the contrary,
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besin than NIFn cells. Among of those stimulants, bradykinin
introduced the greatest response in both NIFr cells and NIFn
cells [15]. NIF (1 mM) reduced nearly 20% of the intracellular
Ca2+ concentration response stimulated by bradykinin in both
NIFr and NIFn cells in the absence of extracellular Ca2+. Since
gingival fibroblasts used in the present study do not possess
L-channel, the target Ca2+ channel for calcium channel block-
ers, the inhibition of intracellular Ca2+ concentration response
by NIF might be another pharmacological effect of NIF.
2.3. Response to growth factors on cell growth
and cell cycle regulators
The growth factor, such as bFGF and insulin-like growth
factor-I (IGF-I), is potent mitogen for fibroblasts that pro-
mote cell cycle progression. Both bFGF and IGF-I are impor-
tant mediators in the development of gingival fibroblasts. We
assumed that there might be some differences between NIFr
and NIFn cells in response to bFGF and IGF-I. Thus, we
compared the differences in cell proliferation, cell cycle,
and expression of cell cycle regulating proteins between NIFr
and NIFn cells in the presence of bFGF and IGF-I.
The proliferation rate of NIFr cells in the presence of bFGF
and IGF-I significantly increased than that of NIFn cells. The
proportionofNIFr cells thathadundergoneprogression to theS
andG2/Mphases from theG0/G1 phase in the presence of bFGF
or IGF-I was greater than that of NIFn cells, and also that
expressions of mRNAs for cyclins A, B1, D1 and E, and cyclin-
dependent kinases (CDKs) 1, 2, 4, and 6 were greater in NIFr
cells than NIFn cells in the presence of bFGF [16,17]. Increases
of phosphor-retinoblastoma (pRB) (Ser807/811), pCDK2
(Thr160), CDK2, and cyclin E protein levels in NIFr cells were
greater than those in NIFn cells, in the presence of bGFG and
IGF-I. In case of bFGF, the elevations of pRB (Ser780), RB, andFigure 1 Relationship between RB, RB kinase, and E2F at G1/S
transition. When RB binds E2F at G1 phase, expression of the
target gene is suppressed. At late G1, RB is phosphorylated
forming pRB by cyclin D-CDK4/6, and then by cyclin E-CDK 2
and cyclin A-CDK2, leading to the release of E2F from RB [18]. In
NIFr cells, pRB (ser807/811) is phosphorylated through cyclin E-
CDK2. RB, retinoblastoma protein; pRB, phosphorylated retino-
blastoma protein; E2F, transcription factor E2F; CDK, cyclin-
dependent kinase.cyclin A protein levels in NIFr cells did not differ from those of
NIFn cells, but pRB(ser780) in case of IGF-I. The growth of NIFr
cells was greater than NIFn cells as a result of the active G1/S
transition of NIFr cells, by the increments of cyclin E, pCDK2
and pRB (ser807/811) protein in NIFr cells [17,18] (Fig. 1).
Therefore, NIFr cells may be more susceptible to the growth
factors in fetal calf serumaswell as bFGF and IGF-I resulting in
increased cyclins and CDKs than NIFn cells.
2.4. Intracellular crosstalk
A possible role of NIF for gingival overgrowth is summarized in
Fig. 2 [18]. NIF inhibits phosphodiesterase to increase protein
kinase G, and then activates p38 mitogen-activated protein
kinase (p38 MAPK) and activating transcription factor-2,
resulting in apoptosis and inhibition of cell growth. Under this
circumstance, NIFn cells were more active than NIFr cells,
indicating NIFn cell growth was depressed by NIF, which also
induced NIFn cells to undergo apoptosis [19]. This was con-
firmed in NIFr and NIFn cells after stimulation by LPS to find
that apoptotic cells inNIFncellswere significantly increasedas
well as p53 and bcl-2mRNA expressions compared to NIFr cells
[20]. NIF did not alter intracellular IP3 level or intracellular
Ca2+ concentration in both NIFr and NIFn cells. However, we
found that NIF increased intracellular diacylglycerol (DAG)
level and protein kinase C (PKC) activity. This indicates that
NIF accelerates phospholipase D activity to produce DAG from
phosphatidic acid and phosphatidylcholine, which then acti-
vates PKC, resulting in the cell growth and cell cycle transition
[21]. bFGF and IGF-I accelerates PKC activity through phos-
pholipase Cg. The relationship between cAMP level and intra-
cellular Ca2+ response elicited by isoprenaline and histamine,
respectively, inNIFr andNIFncellswas investigated tofind that
NIFr cells showed increased intracellular Ca2+ and cAMP levels
[22]. The increase of intracellular Ca2+ level elicited by his-
tamine was depressed by isoprenaline, where NIFn cells
responded more than NIFr cells. A further investigation should
be done to clarify the intermediate pathways.
3. Prevention of gingival overgrowth
3.1. Application of tenidap
Tenidap is a new anti-inflammatory agent, which has been
shown to inhibit IgE-mediated N-acetylglucosaminidase
secretion from mast cells [23], release activated collagenase
from neutrophils [24], inhibit leukotriene B4 and prostanoid
syntheses in human neutrophils [25], form 5-lipoxygenase
products in human subject [26], inhibit production of inter-
leukin-1, 6, and tumor necrosis factor from human Hep3B
hepatoma cells [27], and inhibit the antigen-induced
increase in intracellular Ca2+ and also both antigen- and
thapsigargin-induced Ca2+ influx across the plasma mem-
brane in a mast cell line [28].
We investigated the effect of tenidap on intracellular free
Ca2+ concentration in cultured human gingival fibroblasts.
Tenidap discharges intracellular Ca2+ store, resulting in a
depletion of intracellular Ca2+ store and that tenidap functions
on inhibition of Ca2+ influx in gingival fibroblasts [29]. We also
studied DNA synthesis by means of [3H]-thymidine incorpora-
tion, collagen synthesis bymeansof [3H]-proline incorporation,
Figure 2 A possible role of nifedipine for gingival overgrowth. Nifedipine inhibits PDE to increase PKG, then activate p38 MAPK
resulting in apoptosis and inhibition of cell growth and cell cycle transition (figure modified from Ref. [18]). In this occasion, NIFn cells
weremore active than NIFr cells, indicating NIFn cells were depressed cell growth by nifedipine, as well as NIFn cells undergo apoptosis
by nifedipine. Nifedipine also inhibit PDE to increase PKA which accelerates IP3 induced intracellular Ca
2+ concentration and also
inhibits Ca2+ entry to intracellular Ca2+ store via inhibition of Ca2+-ATPase to result in the deprivation of Ca2+ in the store. Nifedipine
accelerates PLD activity to produce DAG from PA and PC, and then activate PKC, resulting in cell growth, cell cycle transition. Growth
factors, such as bFGF and IGF-I, activates PLCg to activates PKC, resulting in cell growth and cell cycle transition. AP-1, activator
protein 1; AC, adenylate cyclase; DAG, diacylglycerol; GC, guanylate cyclase; IBMX, 3-isobutyl-1-methylxanthine; IGF-I, insulin-like
growth factor-I; IP3, inositol-1, 4, 5-trisphosphate; MEKK-3, MAPK/ERK kinase kinase; NIF, nifedipine; p38, p38 mitogen-activated
protein kinase (MAPK); PA, phosphatidic acid; PC, phosphatidylcholine; PDE, phosphodiesterase; PKA, protein kinase A; PKC, protein
kinase C; PKG, protein kinase G; PLC, phospholipase C; PLD, phospholipase D.
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human gingival fibroblasts. Tenidap inhibited [3H]-thymidine
and [3H]-proline incorporation, depressed cell proliferation,
and lowered intracellular pH [30]. Tenidapenhanced intra- and
extracellular matrix metalloproteinase-1 (MMP-1) concentra-
tions and MMP-1 mRNA expression, and increased phosphory-
lated extracellular signal-regulated kinase 1 (phospho-ERK1)
and phospho-ERK2 in NIFr cells. The previous report that
tenidap depressed synthesis of collagen might be explained
by the increased formation of MMP-1 in NIFr cells. However,
PKC inhibitor (bisindolylmaleimide), MAPK kinase (MEK) 1/2
inhibitor (U0126) and P38 MAPK inhibitor (SB203580) did not
inhibit MMP-1 mRNA expression enhanced by tenidap in NIFr
[31].
Consequently, the present in vitro data suggest that teni-
dap significantly inhibits DNA and collagen syntheses at a
concentration of greater than 20 mM (6.85 mg/mL). In the
first phase of the clinical trial, although plasma Cmax was
8.305, 17.006, and 21.009 mg/mL after a single oral dose of
40, 80, and 120 mg tenidap, respectively (unpublished data,
Pfizer Pharmaceutical Co. Ltd.), more than 99% of tenidap
bound to plasma protein. Cleveland et al. [28] also indicated
that the plasma drug level at therapeutic doses in arthritis
patients reaches 60 mM (20.6 mg/mL), but tenidap is sub-
stantially bound by serum albumin. Therefore, the distribu-
tion of tenidap to oral tissue is hardly available. In case of
rats, the distribution to salivary gland is 17.4—19.7% (unpub-
lished data, Pfizer Pharmaceutical Co. Ltd.). Thus, it could be
estimated that enough tenidap concentration might not beable to reach to the oral tissue, which is enough to reduce
DNA and collagen syntheses in gingival fibroblasts by a sys-
temic tenidap administration. The accumulated collagen
fiber in overgrown gingival tissue is also reduced by intra-
and extracellular MMP-1 activated by tenidap. In our pre-
liminary experiment using rats, the local application of high
dose of tenidap (50 mg/mL, applied into the gingival crevi-
cular region, once a week) might be effective to prevent
gingival overgrowth caused by calcium channel blocker,
especially NIF [32]. The same trend was also found using
dogs. Thus, degree of severity of gingival overgrowth, depth
of gingival crevice, and histopathological findings of gingival
tissue indicated a significant depression of gingival over-
growth by tenidap [33]. Therefore, tenidap may be one of
the drugs that prevent gingival overgrowth. Thus, the con-
tinuous retention of tenidap in local area, such as in period-
ontal pockets, might affect gingival fibroblasts to reduce its
growth through apoptosis.
3.2. Application of 18a-glycyrrhetinic acid
Licorice has been used in cough preparations as well as
sweetening agent in food products. It also has ulcer-healing
properties and mild anti-inflammatory effect. The major
water-soluble constituent of licorice is glycyrrhizin, which
is known to be partly hydrolyzed by glucuronidase to its
aglycone glycyrrhetinic acid which exists in 18 alpha (18a-
GA) and 18 beta stereoisomeric forms [34]. 18a-GA has a
variety of interesting activities such as the growth-promoting
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anti-inflammatory effect [38,39], and an inhibitory effect on
cell proliferation [36]. It has been reported that 18a-GA
induces growth of primary cultured adult rat hepatocytes
[35], down-regulates production of inflammatory chemokine
eotaxin 1 in a human lung fibroblast cell line [38], and inhibits
cell growth in MCF-7 cells [36] and in skin tumors [37].
18a-GA was a good anti-proliferative agent especially on
those tumor cells whose replication rate was slow, by the
inhibition of the onset of progression [36]. Since the growth
rate of NIFr cells was greater than that of NIFn cells, it might
be interesting to clarify if 18a-GA has an activity on the cell
growth of NIFr cells. 18a-GA inhibited cell proliferation and
G1/S transition induced by bFGF in NIFr cells [40]. It was also
shown that cell cycle control proteins, such as pRB(ser780),
pRB(ser807/811), CDK4, CDK6, CDK2, cyclin D1, cyclin A,
were down-stream targets in the growth-inhibition activity
of 18a-GA in NIFr cells. In the development of NIF-induced
gingival overgrowth, an inflammation and the cell growth of
NIFr cells are important factors [9,12,41]. We have recently
demonstrated that 18a-GA increased the number of cells that
underwent apoptosis and decreased G0/G1 phase cells in NIFr.
The mRNA expression of bcl-2, the suppressor for apoptosis,
was suppressed by 18a-GA in NIFr cells but not in NIFn cells.
However, the expression of p53mRNAwas not changed in NIFr
cells [42]. In NIFr and NIFn cells, it was demonstrated that
apoptotic cells in NIFn cells were significantly increased as
well as p53 and bcl-2 mRNA expressions compared to NIFr
cells after stimulation by LPS. Thus, 18a-GA induces apop-
tosis of NIFr cells by inhibiting expression of bcl-2 mRNA.
Based on these findings, 18a-GA, which has anti-inflamma-
tory effect and inhibits growth of NIFr cells, may have a
positive role in NIF-induced gingival overgrowth therapy.
4. Summary
The characters in NIFr and NIFn cells are compared. NIFn cells
tended to undergo apoptosis and increase p53 and bcl-2mRNA
expression in the presence of LPS compared to NIFr cells. NIF
might act in the same manner as that of LPS, indicating the
growth of NIFn cells was depressed in the presence of NIF. NIFr
cells weremore susceptible to calciumchannel blockers in cell
proliferation, DNA and collagen syntheses than NIFn cells. Also
NIFr cells weremore sensitive toNIF and IL-1a accelerated this
sensitivity through bFGF formation.
Tenidap discharged intracellular Ca2+ store, resulting in a
depletion of intracellular Ca2+ store in cultured human gin-
gival fibroblasts. It also inhibited cell growth, DNA and
collagen syntheses, lowered intracellular pH in nicardipine
responder cells, and enhanced MMP-1 formation in NIFr cells.
18a-GA inhibited cell proliferation and G1/S transition
induced in NIFr cells. It was also shown that cell cycle control
proteins were down-stream targets in the growth-inhibition
activity of 18a-GA in NIFr cells. These results suggest that
18a-GA and tenidap might be effective for the prevention of
gingival overgrowth caused by calcium channel blockers.
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